Wedbush Reiterates Outperform on Xenon Pharmaceuticals, Maintains $47 Price Target
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Laura Chico has reiterated an Outperform rating on Xenon Pharmaceuticals (NASDAQ:XENE) and maintained a $47 price target.
August 10, 2023 | 1:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Laura Chico has reiterated an Outperform rating on Xenon Pharmaceuticals and maintained a $47 price target.
The reiteration of an Outperform rating and a maintained price target by a reputable analyst like Laura Chico from Wedbush is a positive signal for Xenon Pharmaceuticals. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100